

Recombinant Mouse IDO (N-6His)

Catalog # EPT074

Expression Host E.coli

DESCRIPTION Recombinant Mouse Indoleamine 2,3-dioxygenase is

produced by our E.coli expression system and the

target gene encoding Met1-Pro407 is expressed with

a 6His tag at the N-terminus.

Accession P28776

Synonyms Indole 2;3-dioxygenase; Indoleamine 2;3-dioxygenase

1; IDO-1; IDO1; IDO; INDO

Mol Mass 47.1 KDa

AP Mol Mass 40-50 KDa, reducing conditions

Purity Greater than 95% as determined by reducing

SDS-PAGE.

Endotoxin Less than 0.1 ng/μg (1 EU/μg) as determined by LAL

test.

FORMULATION Supplied as a 0.2 μ m filtered solution of 20mM

Tris-HCl, 500mM NaCl, 0.01% Tween 80, 1mM EDTA,

50% Glycerol,pH 8.0.



www.elkbiotech.com



RECONSTITUTION

SHIPPING

The product is shipped on dry ice/polar packs.

Upon receipt, store it immediately at the temperature

listed below.

STORAGE

Store at \leq -70°C, stable for 6 months after receipt.

Store at \leq -70 °C, stable for 3 months under sterile

conditions after opening.

Please minimize freeze-thaw cycles.


BACKGROUND

Indoleamine 2,3-dioxygenase (IDO) is a heme enzyme that initiates the oxidative degradation of the least abundant, essential amino acid, I-tryptophan, along the kynurenine pathway. This protein is normally expressed in the dendritic cells, macrophages, microglia, eosinophils, fibroblasts, endothelial cells, and most tumor cells. IDO activity is associated with immunosuppression and immune attenuation. Several studies showed that IDO can contribute to immune escape when expressed directly in tumor cells or when expressed in immunosuppressive antigen presenting cells such as tolerogenic dendritic cells or tumor associated macrophages. IDO also is a promising therapeutic target for the treatment of cancer, chronic





viral infections, and other diseases characterized by pathological immune suppression.



SDS-PAGE



+86-27-59760950